MedTrace Logo

Citalopram Versus Citalopram Plus Pindolol in Major Depressive Disorder

NCT00931775 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2009-07-02

No results posted yet for this study

Summary

The purpose of this study is to examine whether the speed of the clinical antidepressant action of citalopram can be accelerated by administering double doses of pindolol (15 mg/day, tid) which presumably should lead to increased 5-HT1A autoreceptor occupancy.

Conditions

Interventions

DRUG

Pindolol

Pill orally administered. 15 mg/day t.i.d.

Sponsors & Collaborators

  • Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

    lead OTHER

Principal Investigators

  • Enric Álvarez, MD, PhD · Department of Psychiatry. Hospital de la Santa Creu i Sant Pau

  • Víctor Pérez, MD, PhD · Department of Psychiatry. Hospital de la Santa Creu i Sant Pau

  • Francesc Artigas, PhD · Neurochemistry department. Consejo Superior de Investigaciones Científicas

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-12-31
Primary Completion
2005-03-31
Completion
2005-11-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00931775 on ClinicalTrials.gov